Skip to main content
letter
. 2019 Jul 16;34(11):2342–2344. doi: 10.1007/s11606-019-05157-6

Table 1.

Baseline Patient Characteristics Associated with Fluoroquinolone Prescribing

Patient characteristics Academic clinic
N = 56
Non-academic clinic
N = 160
Age (years), mean (SD) 55.9 (14.0) 53.8 (15.3)
Male, n (%) 9 (16.1) 15 (9.4)
Race, n (%)
  African American 41 (73.2) 100 (62.5)
  Hispanic 4 (7.1) 33 (20.6)
  Caucasian 8 (14.3) 18 (11.3)
  Other 3 (5.4) 9 (5.6)
Temperature, n (%)
  ≥ 100.4 (°F) 2 (3.6) 1 (0.6)
White blood cell count (K/mcL), n (%)
  >10.7 1 (1.8) 3 (1.9)
Glomerular filtration rate (mL/min), n (%)
  ≥ 60 44 (78.6) 140 (87.5)
  15–59 11 (19.6) 20 (12.5)
  < 15 and/or hemodialysis 1 (1.8) 0 (0.0)
Failed previous antibiotic therapy, n (%) 9 (16.1) 18 (11.3)
Fluoroquinolone prescribed, n (%)
  Ciprofloxacin 36 (64.3) 136 (85.0)
  Levofloxacin 20 (35.7) 24 (15.0)
Duration of therapy (days), mean (SD) 8.8 (12.0) 6.5 (5.0)
Provider, n (%)
  Attending physician 14 (25.0) 127 (79.4)
  Resident physician 40 (71.4) 2 (1.3)
  Advanced practice provider 2 (3.6) 31 (19.4)
Indication, inappropriate/total prescriptions (% inappropriate)
  Cystitis/pyelonephritis 26/31 (83.9) 125/128 (97.7)
  Upper respiratory tract infection (bronchitis, sinusitis) 3/3 (100) 12/12 (100)
  Intra-abdominal infection/diverticulitis 3/3 (100) 5/8 (62.5)
  Skin and soft tissue infection 1/2 (50.0) 7/9 (77.8)
  Pneumonia 6/9 (66.7) 1/1 (100)
  Osteomyelitis 0/5 (0.0) 0/0 (0.0)
  Otitis externa 0/0 (0.0) 2/2 (100)
  Chronic obstructive pulmonary disease exacerbation 2/2 (100) 0/0 (0.0)
  Prevention of spontaneous bacterial peritonitis 0/1 (0.0) 0/0 (0.0)